Efgartigimod Is an Effective Treatment for Triple‐Seronegative Generalized Myasthenia Gravis: A Report of Three Patients
These patient reports provide preliminary evidence supporting the effectiveness of efgartigimod as a potential alternative treatment for patients with triple-SN gMG who do not respond adequately to traditional therapies. However, multicenter randomized controlled trials are necessary to further evaluate the efficacy and safety of efgartigimod in this patient population.
Authors
- Ruixia Zhu (ORCID: https://orcid.org/0000-0002-2683-4674)
- Ying Zhu (ORCID: https://orcid.org/0000-0003-2078-9806)
- Chi Ma
- Jingyi Shen (ORCID: https://orcid.org/0009-0003-8677-4823)
Institutions
- First Hospital of China Medical University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Muscle & Nerve
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1002/mus.28441
- Citations
- 1
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Liaoning Province